Skip to main content

Advertisement

Log in

Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The BEAM regimen consisting of carmustine (BCNU), etoposide, cytarabine, and melphalan (MEL) is widely used before autologous hematopoietic stem cell transplantation (auto-HSCT) for lymphoma. However, intravenous BCNU is not available in Japan, and therefore, ranimustine (MCNU) has been used instead of BCNU (the MEAM regimen). We retrospectively analyzed the outcome of 79 adult patients who underwent auto-HSCT for lymphoma using this regimen in two centers, with 1- and 2-day dosing of MEL, respectively. Three-year overall survival (OS) and progression-free survival (PFS) probabilities were 77.3 and 56.5 % in the entire population and 71.7 and 58.0 % in patients with diffuse large B cell lymphoma. These outcomes were at least equivalent to those with the BEAM regimen. There was no regimen-related pulmonary toxicity. In a multivariate analysis, older age was the only factor that was significantly associated with for OS. In a comparison of the two MEL dosing schedules, while there was no significant differences in either OS or PFS, diarrhea was observed more frequently with 1-day dosing of MEL. In conclusion, the MEAM regimen appeared to be a promising conditioning regimen in auto-HSCT for lymphoma. A large prospective study is warranted to confirm the current findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. (2011) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 17:18–19.

  2. Jantunen E, Sureda A (2012) The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant 18:660–673

    Article  PubMed  Google Scholar 

  3. Perales MA, Ceberio I, Armand P et al (2015) Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21:971–983

    Article  PubMed  Google Scholar 

  4. Oliansky DM, Gordon LI, King J et al (2010) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 16:443–468

    Article  CAS  PubMed  Google Scholar 

  5. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545

    Article  CAS  PubMed  Google Scholar 

  6. Stiff PJ, Unger JM, Cook JR et al (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 369:1681–1690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071

    Article  CAS  PubMed  Google Scholar 

  8. Salar A, Sierra J, Gandarillas M et al (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant 27:405–412

    Article  CAS  PubMed  Google Scholar 

  9. Chen YB, Lane AA, Logan BR et al (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1046–1053

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kim JE, Lee DH, Yoo C et al (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35:183–187

    Article  CAS  PubMed  Google Scholar 

  11. Kato J, Mori T, Yokoyama K et al (2011) Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplant 46:923–928

    Article  CAS  PubMed  Google Scholar 

  12. Zhang C, Chen XH, Liu J et al (2015) Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia. J Clin Pharm Ther 40:336–338

    Article  CAS  PubMed  Google Scholar 

  13. Kawamura K, Hayakawa J, Akahoshi Y et al (2015) Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol 102:230–237

    Article  CAS  PubMed  Google Scholar 

  14. Kanda Y (2013) Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 48:452–458

    Article  CAS  PubMed  Google Scholar 

  15. Parmar SR, Bookout R, Shapiro JF et al (2014) Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 49:761–766

    Article  CAS  PubMed  Google Scholar 

  16. Visani G, Malerba L, Stefani PM et al (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118:3419–3425

    Article  CAS  PubMed  Google Scholar 

  17. Sellner L, Boumendil A, Finel H et al (2016) Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant 51:212–218

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoshinobu Kanda.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest relevant to the subject of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sugimoto, M., Ito, S., Mashima, K. et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol 95, 1513–1519 (2016). https://doi.org/10.1007/s00277-016-2740-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2740-9

Keywords

Navigation